Sunday 11 October 2026 Export all EQ data to Excel Powerpack

Equillium, Inc.

EQ Healthcare Biotechnology

Equillium, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $41.1 million, up 13.9% from fiscal 2023. In the quarter to June 2026, revenue fell 52.3%, EPS grew 75.0% and free cash flow fell 38.7%, each against the same quarter a year earlier. Dividend growth for three consecutive years, revenue growth for three.

1.41 0.03 −2.08%
Market cap
$91.3M
P/E
0.0×
Fwd P/E
−5.2×
Dividend yield
—
F-score
3/9
Altman Z
−6.75
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
23.40 18.62 10.58 10.85
Net Debt/EBITDA
11.15 10.98 7.69 7.28
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.04) (0.04) (0.06) (0.13)
Book value per Share
0.50 0.62 0.50 0.47
Free Cash Flow
(4.18) (4.30) (3.16) (8.43)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates